USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme, and Protein Therapy
Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme, and Protein Therapy
13-Dec-2019
Global
$950.00
Special Price $712.50 save 25 %
Description
This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across biosimilars, gene therapy, microbiome, robotics, ribozyme, and protein therapy. The TOE also provides technological analysis for recent developments in animal protein applications, microbiome, and cell cultures.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Alytix, Phage Therapy, Amega, Biosimilars, Nanotechnology, Biotechnology, Gene Therapy, AskBio, Unicorn, Konica Minolta, Artifical Intelligence, Healthcare, SoftBank, Superintelligence, Ranomics, High-throughput Screening, VariantFind, aBioBot Inc., Robot Assistant, DoseBiome, Oral Microbiome, Clara Foods, Egg Whites, Cell Culture, Clara Foods, Animal Protein, Circularis, Ribozyme, Protein Production, SyntheX Labs, Peptide Therapeutics, Cancer, Rare Diseases, MycoWorks, Sustainable Leather, mFluiDx Inc., Automated Point-of-care DNA Diagnostic, ARDA, Cosmetics, Food, Fragrance, Aurinia Pharmaceuticals, Voclosporin, Lupus Nephritis, Omeros, Monoclonal Antibody, Microangiopathy, Narsoplimab, Ethicon, Sealant Spray, Bleeding, Surgery. Ardelyx, Chronic Kidney Disease, Neurological Disorder, Microbiome, Obesity, Metabolic Disorder
Table of Contents
Recent Advancements in the Biotech Industry
- Alytix
- Alytix
- Amega Biotech
- Amega Biotech
- AskBio
- AskBio
- Konica Minolta
- Konica Minolta
- SoftBank
- SoftBank
- Ranomics Inc.
- Ranomics Inc.,
- aBioBot Inc.
- aBioBot Inc.
- DoseBiome
- DoseBiome
- Clara Foods
- Clara Foods
- Circularis Biotechnologies Inc.
- Circularis Biotechnologies Inc.
- SyntheX Labs
- SyntheX Labs
- MycoWorks
- MycoWorks
- mFluiDx Inc.
- mFluiDx Inc.
- ARDA
- ARDA
- Aurinia Pharmaceuticals
- Aurinia Pharmaceuticals
- Omeros
- Omeros
- Johnson & Johnson’s Ethicon
- Johnson & Johnson’s Ethicon
- Ardelyx
- Ardelyx
- Brigham and Women’s Hospital
- Brigham and Women’s Hospital
- University of Utah
- University of Utah
Key Industry Contacts
- Key Contacts
- Key Contacts (continued)
- Key Contacts (continued)
- Key Contacts (continued)
- Your F&S Thought Leader
Related Research
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | D759-00-0F-00-00 |
| Is Prebook | No |
| Ti Codes | D759 |